[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539467":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":50,"collaborators":52,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":34,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":34,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":83,"whyStopped":34,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"NextFertility","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group DSG: Desogestrel","ACTIVE_COMPARATOR","Desogestrel Cerazet® 75 mg\u002Fday orally from the first day of controlled ovarian hyperstimulation (COH) until the day of trigger with agonist (GnRH-a).",[13],"Drug: Cerazet",{"label":15,"type":10,"description":16,"interventionNames":17},"Group MPA: Medroxyprogesterone","Medroxyprogesterone acetate Progevera® 10 mg\u002Fday orally from the first day of controlled ovarian hyperstimulation (COH) until the day of trigger with agonist (GnRH-a).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Cerazet","Comparation of the utilization of two distinct progestogens for pituitary suppression",[9,15],[25],"Progevera",[27],{"name":28,"affiliation":5,"role":29},"Luis Quintero","STUDY_CHAIR",[31],{"name":28,"role":32,"phone":33,"phoneExt":34,"email":35},"CONTACT","+34 963160240",null,"luis.quintero@next-clinics.com",[37],{"facility":5,"status":34,"city":38,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Valencia","46009","Spain","ES",{"type":43,"coordinates":44},"Point",[45,46],-0.37966,39.47391,{"lat":46,"lon":45},[49],{"name":28,"role":32,"phone":33,"phoneExt":34,"email":35},{"type":51,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR",[53],{"name":54,"class":55},"SINAE SL","UNKNOWN","100539467","comparison-of-two-ppos-models-for-pituitary-suppression-100539467",false,"NCT06304220","Comparison of Two PPOS Models for Pituitary Suppression","Comparación de Dos Modelos de PPOS Para supresión Hipofisaria en Ciclos de estimulación ovárica, Desogestrel vs Medroxiprogesterona","Inclusion Criteria:\n\n* BMI of 18-29,9 kg\u002Fm2\n* Ultrasound count of antral follicles prior to COH ≥ 12 follicles\n* Meeting the criteria for inclusion in the egg donation program\n* Normal karyotype and no active sexually transmitted diseases\n* No use of combined hormonal contraceptives one month before COH\n\nExclusion Criteria:\n\n* Patients excluded from the egg donation program\n* Untreated sexually transmitted diseases, positive serology for HBV, HIV, HCV\n* Blood disorders, neurodegenerative\u002Fpsychiatric diseases, carriers of X-linked genetic diseases, oncological diseases, endometriosis.\n* Oligomenorrhea (\\\u003C1 menstrual cycle in 3 months)\n* Use of combined hormonal contraceptives before COH",true,"FEMALE","18 Years","34 Years",{"count":68,"type":69},210,"ESTIMATED","INTERVENTIONAL",[72],"NA","The scarcity of evidence regarding the interchangeable use of different progestogens poses challenges, particularly in international egg donation and fertility preservation programs where standardizing protocols is crucial for achieving consistent efficacy, efficiency, and safety outcomes. Consequently, there's a pressing need for clinical studies to assess the effects of various progestogens on clinical outcomes in controlled ovarian hyperstimulation cycles. This study, a pioneering effort, aims to compare the effects of two progestogens on oocyte performance, safety, and efficiency in an egg donation program involving young, healthy, normo-responding patients.",[75,76],"Infertility, Female","Fertility Disorders",[78,79,80,81,82],"Primed-progestin ovarian stimulation protocol","Quality of oocytes","Oocyte yield","Ovarian Sensitivty Index","Controlled ovarian hyperstimulation","NOT_YET_RECRUITING","2024-06-17",{"date":86,"type":87},"2024-06-18","ACTUAL",{"date":89,"type":69},"2024-07",{"date":91,"type":69},"2024-12",{"name":5,"class":6},1]